Share this article on:

Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis: P-19

Colombel, Jean-Frédéric1; Sandborn, William2; Wolf, Doug3; Panaccione, Remo4; Lazar, Andreas5; Kron, Martina5; Robinson, Anne6; Thakkar, Roopal6

Abstracts from the 2012 Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation's National Clinical & Research Conference December 13–15, 2012 Hollywood, Florida: Clinical Poster Presentations

1Hopital Huriez, CHRU, Lille, Nord, France,

2University of California San Diego, La Jolla, CA, USA,

3Atlanta Gastroenterology Associates, Atlanta, GA, USA,

4University of Calgary, Calgary, AB, Canada,

5Abbott GmbH & Co. KG, Ludwigshafen, Germany,

6Abbott Laboratories, Abbott Park, IL, USA

© Crohn's & Colitis Foundation of America, Inc.